VistaGen Therapeutics, Inc. (VTGN)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about VistaGen Therapeutics, Inc. (VTGN)
Go deeper and ask any question about VTGN
Company Performance
Current Price
as of Sep 13, 2024$3.29
P/E Ratio
N/A
Market Cap
$89.01M
Description
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Metrics
Overview
- HQSouth San Francisco, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerVTGN
- Price$3.29+3.13%
Trading Information
- Market Cap$89.01M
- Float89.85%
- Average Daily Volume (1m)95,237
- Average Daily Volume (3m)102,223
- EPS-$1.58
Company
- Revenue$0.97M
- Rev Growth (1yr)-52.70%
- Net Income-$10.73M
- Gross Margin-79.76%
- EBITDA Margin-14,261.90%
- EBITDA-$11.98M
- EV$0.13M
- EV/Revenue0.13
- P/EN/A
- P/S103.76